In a nutshell This study investigated the effectiveness and safety of increasing the dose of solifenacin (Vesicare) treatment in male patients with overactive bladder (OAB) that does not respond to low-dose treatment. Researchers suggested that increasing the dose of solifenacin is safe and improves the outcomes of these patients. Some...
Read More
In a nutshell This study investigated the effectiveness and impact on patient satisfaction of mirabegron (Myrbetriq) in patients with overactive bladder (OAB). Researchers suggested that this drug improved the treatment satisfaction of patients with OAB. Some background OAB consists of an uncontrollable need to urinate with or without incontinence...
Read MoreIn a nutshell This study investigated the risk of retreatment after 3 or 6 months of antimuscarinic therapy for overactive bladder (OAB). This study found that prolonged antimuscarinic treatment does not increase the risk of retreatment for OAB. Some background Overactive bladder (OAB) occurs when the bladder muscle is too active....
Read More
In a nutshell This study looked at overactive bladder (OAB) symptoms after prostate removal. It found that there are many treatment options for the symptoms. Some background Overactive Bladder (OAB) is a sudden, frequent urge to urinate. It may result in urge incontinence. This is an inability to hold on to urine. OAB...
Read More
In a nutshell This study looked at the long term value for money of two drugs for Overactive Bladder Syndrome (OAB). It concluded that Mirabegron (Myrbetriq) is more value for money than Tolterodine (Detrol). Some background Overactive Bladder (OAB) is a sudden, frequent urge to urinate. It may result in urge incontinence...
Read More
